IFB Health Economic Evaluations 2025

Introduction:

IFB Health Economic Evaluations 2025: RENEWED COURSE!

A unique 2-day course with theory, practical exercises and workshops on state-of-the art cases.
Participants interact personally with leading academics and authorities.


In the current health care context, efficacy and safety of medicines are no longer sufficient for successful market access.
Innovative treatments, medical devices and diagnostics need to show added therapeutical value and provide “value for money”. 

This IFB course gives thorough insights in the concepts and principles of health economic evaluations and health technology assessment (HTA) with a focus on the Belgian context and including the latest updates on the EU Joint Clinical Assessment (JCA).

These evaluations have become key requirements in the development and reimbursement of new treatments, since authorities allocate available budgets to those treatments that provide the most health gain for each Euro invested.

The course also focuses on new, hot issues, such as Real World Data and Indirect Treatment Comparisons.
Participants get the latest updates on the Roadmap towards the reform of the reimbursement process and on the Belgian health economic guidelines.

This IFB course gives a practical view on the way Health Economic Evaluations are built in the context of reimbursement submissions and provides basic technical insights which allows you to interact more efficiently with Health Economic experts and authorities.

Timing:

Preliminary dates 2025: January 30-31 - 2025  (Thursday & Friday from 9.00-17.00h)

 

Detailed program:

30/01/2025  
 8.30h Reception with coffee
 9.00-12.30h

 Introduction to health economic evaluations - Lieven Annemans

  • challenges of current health policies; why health economic evaluations.
  • definitions, concepts, principles of health economic evaluations and Health Technology Assessment HTA.
  • introduction to the QALY: from theory to practice
  • thresholds for Societal willingness to pay for Health Gains
 13.30-17.00h

 Methods for health economic evaluations - Lieven Annemans 

  • health Economic models – decision trees, Markov models
  • uncertainty analysis in health economic models
  • principles of cost analysis and budget impact analysis
  • the use of clinical trials in health economic evaluations: dos and don’ts
  • state of the art regarding the EU Joint Clinical Assessment (JCA)

 

31/01/2025
 8.30h  Reception with coffee
 9.00-12.30h

Step by step exploration of a health economic analysis - Karen Moeremans

Participants receive a fictive health economic model in MS Excel.
They are guided through the development of this model and observe how the theory is put into practice.
Through exploration of this model and practical exercises, participants become more familiar with the technical aspects of health economic evaluations in daily practice:

  • study design
  • the steps required to complete a cost-utility and budget impact analysis
  • technical modelling methods in practice
  • finding the right data inputs
  • presentation and interpretation of results and sensitivity analyses 

Participants are requested to bring their laptop for exercises and exploration of the model in MS Excel.

 13.30- 15.30h

Belgian guidelines for health economic evaluations and reporting (KCE) - Barbara Claus - presented with a focus on:

  • key challenges in reimbursement files
  • the process of contract negotiations
  • the roadmap towards the reform of the reimbursement process
  • EU initiatives regarding HTA
15.30-17.00h

Health economic evaluations and HTA in decision making on reimbursement:  challenges and trends - Lieven Annemans

  • the use of real world data and real world evidence
  • precision medicine: promises and pitfalls
  • from market access to patient access: hurdles and solutions
  • integrating health economics in the product development strategy

 

Your speakers / Faculty members: for more details see under

 

Lieven Annemans:

Lieven Annemans, PhD, MMan, MSc, Full Professor of health economics, Ghent University and consultant at INFOHECO. He is Past President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, and ex-advisor to the Minister of Social Affairs. He has > 25 years of experience in health-economic evaluations of pharmaceutical drugs, vaccines, medical devices, diagnostics, and preventive health actions in various medical areas. His main research interests are epidemiological models, Health Technology Assessment (HTA), retrospective/prospective health-economic evaluations, and physician payment systems. He has published > 300 papers in peer-reviewed journals and has given hundreds of lectures and trainings on health-economic evaluations and HTA.
He is author of the book “Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations” (Pelckmans Pro 2018). His other books "De prijs van uw gezondheid"(2014)  and "Je geld of je leven in de gezondheidszorg" (2017) show the challenges of the Belgian Health system and proposed solutions.  
 

Karen Moeremans:

Managing partner and health economist at CHESS. Karen graduated as MD in 1993. Karen worked for several years in pharmaceutical industry as a CRA and medical advisor. Since 1998 Karen has been conducting and managing health economic projects, first as health scientist at HEDM, later as consultant, senior consultant and director of Health Economics and Outcomes Research (HEOR) at IMS Health Consulting. In 2013, Karen joined CHESS, a small-scale company striving to provide high quality-driven consulting services in health economic simulations and strategies. During these 20 years in health economics, Karen’s work has involved the management, conduct, supervision and quality assurance of HEOR projects, both at a national and international level. She gained experience in health economic evaluations in a wide range of disease areas such as oncology, hematological oncology, gynaecology, ophthalmology, dermatology, infectious diseases, psychiatric diseases, neurology, vaccines... . Her broad experience encompasses health economic modelling, cost-effectiveness and cost-utility evaluations, cost of illness studies, budget impact analysis…   At CHESS Karen is responsible for the conduct or the quality assurance of health economic projects which include performing cost-effectiveness and budget impact analyses for reimbursement dossiers, developing global economic models, performing technical model validations, …
 

Barbara Claus: 

Barbara Claus is a hospital pharmacist (since 2002) and currently works at the Ghent University Hospital in Belgium. She is also vice president of the CTG/CRM.
She is a member of the pharmacotherapeutic committee at the Ghent University Hospital and is responsible for accurate and efficient use (clinical pharmacy) of drugs. 
She obtained her PhD in Medical Sciences in 2015 with a research topic in the domain of clinical pharmacy and pharmacoeconomics and is now visiting professor at the Faculty of Pharmaceutical Sciences and the Faculty of Medicine and Health Sciences at Ghent University. In the previous years, she was a research member and author for several projects of the Federal Public Service of Health and was involved in the national policy group on drug shortages in Belgium until 2023.
Her past involvement as vice-president (2011-2012) and as president (2012-2014) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Student Chapter of Belgium highlights her interest in efficient use of drugs.
She also led a special interest group of pharmacoeconomics of the European Society of Clinical Pharmacy between 2018 and 2020. 

 

Moderator: Dirk Broeckx (IFB)

 

Where?

This 2 day training will take place in Brussels (Grand-Bigard/ Groot-Bijgaarden) - Salons Waerboom and is non-residential. 

 

Language?

English.

 

Price?

• The 2-day training::
o Seminar fee: 1.646 € (excl. VAT)
o Catering for 2 days  ( including lunches, breaks,…): 205 € (excl. Vat)

 

Price reductions?

• IFB members receive a 5 % discount
• For non-profit organizations we offer a 50% discount.

Small and medium enterprises (SMEs) can profit from the KMO portefeuille (www.kmo-portefeuille.be or call 1700 for more information).

 

 

Copyright © 2024, All rights reserved.